Page last updated: 2024-11-05

4-fluoroamphetamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-fluoroamphetamine: RN given refers to parent cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9986
CHEMBL ID2009392
SCHEMBL ID712487
MeSH IDM0120924

Synonyms (43)

Synonym
NCIOPEN2_001428
NCI60_042091
p-fluoroamphetamine
phenethylamine, p-fluoro-alpha-methyl-
4-fluoro-alpha-methylphenethylamine
benzeneethanamine, p-fluoro-alpha-methyl-
4-fluoroamphetamine
p-fluoro-alpha-methylphenethylamine
AKOS000148841
1-(4-fluorophenyl)propan-2-amine
1-(4-fluorophenyl)propane-2-amine
459-02-9
4-fa
unii-s5744xyr1z
(+-)-p-fluoroamphetamine
s5744xyr1z ,
2-(4-fluoro-phenyl)-1-methyl-ethylamine
SCHEMBL712487
AKOS022196416
(+/-)-2-(4-fluoro-phenyl)-1-methyl-ethyl-amine
AB76425
(1s)-2-(4-fluorophenyl)-1-methylethylamine
72522-20-4
(1r)-2-(4-fluorophenyl)-1-methylethylamine
788123-23-9
AB76433
CHEMBL2009392
1-(4-fluorophenyl)-2-propanamine #
4-fluoro-.alpha.-methylphenethylamine
p-fluoro-.alpha.-methylphenethylamine
(rs)-1-(4-fluorophenyl)propan-2-amine
phenethylamine, p-fluoro-.alpha.-methyl-
j50.057g ,
1-(4-fluorophenyl)-2-propaneamine
pal-303
benzeneethanamine, 4-fluoro-.alpha.-methyl-
(+/-)-p-fluoroamphetamine
4-fmp
AC-26261
1-(4-fluorophenyl)-2-propylamine
DTXSID90894758
Q229962
PD048378

Research Excerpts

Toxicity

All patients experienced adverse effects after 4-fluoroamphetamine use.

ExcerptReferenceRelevance
"We study adverse health effects after use of the new psychoactive substance 4-fluoroamphetamine."( Fatalities, Cerebral Hemorrhage, and Severe Cardiovascular Toxicity After Exposure to the New Psychoactive Substance 4-Fluoroamphetamine: A Prospective Cohort Study.
Brunt, TM; de Vries, I; Hondebrink, L; Nugteren-van Lonkhuyzen, JJ; Rietjens, SJ; Smink, BE; Soerdjbalie-Maikoe, V; van Riel, AJHP; Venhuis, B, 2018
)
0.92
" All patients experienced adverse effects after 4-fluoroamphetamine use."( Fatalities, Cerebral Hemorrhage, and Severe Cardiovascular Toxicity After Exposure to the New Psychoactive Substance 4-Fluoroamphetamine: A Prospective Cohort Study.
Brunt, TM; de Vries, I; Hondebrink, L; Nugteren-van Lonkhuyzen, JJ; Rietjens, SJ; Smink, BE; Soerdjbalie-Maikoe, V; van Riel, AJHP; Venhuis, B, 2018
)
0.95

Pharmacokinetics

ExcerptReferenceRelevance
" Therefore, a controlled study was performed to evaluate pharmacokinetic parameters of 4-fluoroamphetamine (4-FA) in humans and to compare it with effects."( Pharmacokinetic properties of 4-fluoroamphetamine in serum and oral fluid after oral ingestion.
de Sousa Fernandes Perna, E; Kuypers, KPC; Paulke, A; Pogoda, W; Ramaekers, JG; Schneider, D; Theunissen, EL; Toennes, SW; Wunder, C, 2019
)
1.03
" The elimination half-life was approximately 8-9 hours and shorter than that of amphetamine but it exhibited a marked variation (5."( Pharmacokinetic properties of 4-fluoroamphetamine in serum and oral fluid after oral ingestion.
de Sousa Fernandes Perna, E; Kuypers, KPC; Paulke, A; Pogoda, W; Ramaekers, JG; Schneider, D; Theunissen, EL; Toennes, SW; Wunder, C, 2019
)
0.8
"The pharmacokinetic properties of 4-FA are similar to that of amphetamine including a marked variation in elimination."( Pharmacokinetic properties of 4-fluoroamphetamine in serum and oral fluid after oral ingestion.
de Sousa Fernandes Perna, E; Kuypers, KPC; Paulke, A; Pogoda, W; Ramaekers, JG; Schneider, D; Theunissen, EL; Toennes, SW; Wunder, C, 2019
)
0.8

Dosage Studied

ExcerptRelevanceReference
"Primary outcome measures were (i) the percentage of samples purchased on-line and (ii) the chemical purity of powders (or dosage per tablet); adulteration; and the price per gram, blotter or tablet of drugs bought on-line compared with drugs bought off-line."( Purity, adulteration and price of drugs bought on-line versus off-line in the Netherlands.
Brunt, TM; van der Gouwe, D; van der Pol, P; van Laar, M, 2017
)
0.46
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (33)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (9.09)18.7374
1990's1 (3.03)18.2507
2000's0 (0.00)29.6817
2010's22 (66.67)24.3611
2020's7 (21.21)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 37.31

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index37.31 (24.57)
Research Supply Index3.66 (2.92)
Research Growth Index4.23 (4.65)
Search Engine Demand Index53.49 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (37.31)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (11.76%)5.53%
Reviews3 (8.82%)6.00%
Case Studies6 (17.65%)4.05%
Observational0 (0.00%)0.25%
Other21 (61.76%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]